跳至主要内容
临床试验/NCT02327819
NCT02327819Unknown不适用

The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Tel-Aviv Sourasky Medical Center1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2015年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
time until a new liver tumor is found

研究概览

简要总结

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown.

The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •diagnosed primary liver cancer
  • •viral or Nonalcoholic Steatohepatitis Cirrhosis
  • •Cirrhosis rated Child-Pugh A
  • •liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A

排除标准

  • •Age (over 65)
  • •liver condition rated Child-Pugh B/C
  • •GI/Absorption issues
  • •patients given a treatment before surgery

研究组 & 干预措施

BCAA supplement

Active Comparator

Branched-chain amino acids supplement, 12 g/day

干预措施: Branched-chain amoni acids (BCAA) (Dietary Supplement)

non-BCAA protein supplement

Sham Comparator

non-BCAA protein supplement

干预措施: non-BCAA protein supplement (Dietary Supplement)

结局指标

主要结局

time until a new liver tumor is found

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验